Trials Sponsors Conditions Drugs Pricing

Conditions

Parkinson Disease

Keywords

continuous infusionpersonality

Outcome Measures

Primary Outcomes (2)

percent of improvement of quality of life score at 6 months after the beginning of the second line treatment
Evaluation of life quality using Parkinson's Disease Questionnaire (PDQ-39) scale before (day 1) and after (6 month) the starting of perfusion treatment
day 1
percent of improvement of quality of life score at 6 months after the beginning of the second line treatment
Evaluation of life quality using PDQ-39 scale before and after the starting of perfusion treatment
6 months

Study Arms (1)

Patients having Parkinson's disease

Parkinson's patients presenting motor fluctuations and/or disabling dyskinesia and in need of the establishment of a second line treatment by subcutaneous apomorphine infusion or intrajejunal infusion of levodopa-carbidopa in the context of classical care of their Parkinson's disease. Patients will have TCI scale and PDQ-39 scale.

Other: TCI scaleOther: PDQ-39 scale

Interventions

TCI scaleOther

TCI scale : Evaluation of the patient's personality with the TCI before that the treatment by continuous infusion started.

Also known as: Temperament and Character Inventory scale (TCI), Quality of life scale

Patients having Parkinson's disease

PDQ-39 scaleOther

PDQ-39 scale: Comparison of life quality before and after the starting of he treatment by continuous infusion.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Parkinson patients

You may qualify if:

Patients having Parkinson's disease according to United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) criteria

Sponsors & Collaborators

University Hospital, Toulouse
Otherlead

Study Sites (1)

UHToulouse

Toulouse, 31000, France

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Officials

Chrisitine BREFEL COURBON, PH
University Hospital, Toulouse
PRINCIPAL INVESTIGATOR

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 21, 2018

First Posted

January 4, 2019

Study Start

December 18, 2018

Actual (reported)

Primary Completion

December 18, 2020

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Personality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs, in Parkinson's Disease

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Study Arms (1)

Patients having Parkinson's disease

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Study Arms (1)

Patients having Parkinson's disease

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations